Ponatinib Plus Reduced-intensity Chemotherapy in the First-line Treatment of Adult Patients With Ph+ ALL
A legfontosabb adatok
- Ki végzi
- Institute of Hematology and Blood Transfusion, Czech Republic
- Hol
- Csehország7 helyszín, 1 országbanVálassz országot a helyszínekhez
- Azonosító
- Állapot
- Leállítva
- Fázis
- 2. fázis
- Résztvevők
- 4 fő vett részt
- Kezdés
- 2021. febr. 16.
- Befejezés
- 2024. júl. 1.
- A vizsgálat típusa
- Beavatkozással járó
- A vizsgált kezelések
- Ponatinib 15 MG Oral Tablet
- A regiszteradat frissítve
- 2024. augusztus 14.
- Miért állt le
- slower recruitment rate;
Ki vehet részt
- Életkor
- 18 év – 99 év
- Nem
- Nők és férfiak
- Egészséges önkéntesek
- Nem vehetnek részt
A regiszter feltételei, szó szerint
Mind a 24 feltétel megnézéseKevesebb
Ki vehet részt
- Patients with newly diagnosed, previously untreated, Ph-positive [either t(9;22) and/or BCR-ABL positive] B-precursor acute lymphoblastic leukemia
- Age more than 18 years
- Eligible to intensive chemotherapy, due to general health status
- ECOG (Eastern Cooperative Oncology Group) performance status ≤2
- Absence of significant liver disease, as defined by the following criteria: total serum bilirubin ≤1.5 x upper limit of normal (ULN), unless due to Gilbert's syndrome, alanine aminotransferase (ALT) ≤2.5 × ULN or ≤5 x ULN if leukemic involvement of the liver is present, and aspartate aminotransferase (AST) ≤2.5 × ULN or ≤5 x ULN if leukemic involvement of the liver is present
- Adequate pancreatic function as defined by serum amylase and lipase ≤1.5 × ULN
- Diagnostic sample of bone marrow (or peripheral blood with >50% of blasts) available for central MRD assessment
- Subject has provided written informed consent prior to any screening procedure
Ki nem vehet részt
- Taking any medications or herbal supplements that are known to be strong inhibitors of CYP3A4 within at least 14 days before the first dose of ponatinib
- Female patients who are pregnant or breast feeding or patients of childbearing potential not willing to use a highly effective method of contraception during the study and for 3 months following the last dose of study drug
- Any concurrent severe and/or uncontrolled medical condition, which could, in the opinion of the investigator, compromise participation in the study
- Concurrent participation in another clinical study with an investigational medical product
- Active serious infection not controlled by oral or intravenous antibiotics
- Active known hepatitis B virus (HBV) or hepatitis C virus (HCV) or positive HIV serology
- History of acute pancreatitis within 1 year of study or history of chronic pancreatitis
- Uncontrolled hypertension (diastolic blood pressure >90 mmHg; systolic >140 mmHg). Patients with hypertension should be under treatment on study entry to effect blood pressure control
- GI disease and/or major GI surgery that may significantly alter the absorption of study drug
- Hypersensitivity to the active substance or to any of the excipients, especially galactose intolerance
- Patients with a history of another primary malignancy that is currently clinically significant or currently requires active intervention
- Clinically significant, uncontrolled or active cardiovascular disease, specifically including, but not restricted to: any history of myocardial infarction, stroke, or revascularization; unstable angina or transient ischemic attack within 6 months prior to enrolment; congestive heart failure within 6 months prior to enrolment or left ventricular ejection fraction (LVEF) less than lower limit of normal per local institutional standards; history of clinically significant (as determined by the treating physician) atrial arrhythmia; any history of ventricular arrhythmia; any history of venous thromboembolism including deep venous thrombosis or pulmonary embolism
- Creatinine levels > 160 µmol/L or estimated creatinine clearance of < 50 mL/min
- Lymphoid blast crisis of chronic myelocytic leukemia (CML)
- Uncontrolled hypertriglyceridemia (triglycerides > 5.1 µmol/L)
- Male patients whose sexual partner(s) are women of childbearing potential who are not willing to use a highly effective method of contraception, one of which includes a condom, during the study
Hol van ez a vizsgálat?
Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.
A vizsgálatról
Mit akar kideríteni a vizsgálat
This is a phase II interventional trial to evaluate the efficacy of ponatinib plus reduced-intensity chemotherapy in the first-line treatment of adult patients with Ph+ acute lymphoblastic leukemia. This combination has the potential to improve the depth of molecular responses after the induction phase of treatment. Patients who achieve a complete molecular response (CMR) at week 11 will not be directed to alloSCT and will receive consolidation chemotherapy combined with ponatinib, followed by 24 months of ponatinib maintenance. The aim is to spare individuals with a low probability of relapse from overtreatment with more intensive and toxic transplant procedure.
A vizsgálat csoportja
- ponatinib plus reduced-intensity chemotherapyA vizsgált kezelés
ponatinib plus reduced-intensity chemotherapy in first-line treatment of Adult Ph+ ALL
Kezelés: Ponatinib 15 MG Oral Tablet
Adatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- Hivatalos cím
- Ponatinib Plus Reduced-intensity Chemotherapy in the First-line Treatment of Adult Patients With Ph-positive Acute Lymphoblastic Leukemia
- A regiszteradat frissítve
- 2024. augusztus 14.